Compounds > desoxyepothilone b
Page last updated: 2024-09-27

desoxyepothilone b

Description

desoxyepothilone B: microtubule-targeted antitumor agent; lacking the epoxide of epothilone B; may be equiv to epothilone D [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

epothilone D : An epithilone that is epithilone C in which the hydrogen at position 13 of the oxacyclohexadec-13-ene-2,6-dione macrocycle has been replaced by a methyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID447865
CHEMBL ID96172
CHEBI ID29579
SCHEMBL ID4415
MeSH IDM0294240

Synonyms (59)

Synonym
chebi:29579 ,
12,13-desoxyepothilone b, cis
R1492 ,
CHEMBL96172
HY-15278
(4s-(4r*,8r*,9r*,13z,16r*(e)))-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-(1-methyl-2-(2-methyl-4-thiazolyl)ethenyl)oxacyclohexadec-13-ene-2,6-dione
nsc-703147
12,13-desoxy-epothilone b
kos-862
(-)-desoxyepothilone b
depob
nsc-721085
biologically synthesized epothilone d
z-12,13-desoxyepothilone b
nsc721085
(-)-epothilone d
12,13-deoxyepothilone b
oxacyclohexadec-13-ene-2,6-dione, 4,6-dihydroxy-5,5,7,9,13-pentamethyl-16-((1e)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl)-, (4s,7r,8s,9s,13z,16s)-
nsc 703147
oxacyclohexadec-13-ene-2,6-dione, 4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-(1-methyl-2-(2-methyl-4-thiazolyl)ethenyl)-, (4s-(4r*,7s,8r*,9r*,13z,16r*(e)))-
EPD ,
epothilone d
desoxyepothilone b
189453-10-9
DB01873
12,13-desoxyepothilone b
kos 862
nsc703147
LMPK04000001
(4s,7r,8s,9s,13z,16s)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione
epothiolone d
unii-t0358e0yuf
epothilone b, desoxy
kos862
t0358e0yuf ,
depob cpd
epothilon d
CS-0655
epo d
AM81237
oxacyclohexadec-13-ene-2,6-dione, 4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(1e)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (4s,7r,8s,9s,13z,16s)-
SCHEMBL4415
oxacyclohexadec-13-ene-2,6-dione, 4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-((1e)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl)-, (4s,7r,8s,9s,13z,16s)-
epothilone d [who-dd]
epothilone d [mi]
(4s,7r,8s,9s,13z,16s)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(e)-1-methyl-2-(2-methylthiazol-4-yl)vinyl]-1-oxacyclohexadec-13-ene-2,6-dione
XOZIUKBZLSUILX-GIQCAXHBSA-N
(4s,7r,8s,9s,13z,16s)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(1e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]oxacyclohexadec-13-ene-2,6-dione
(4s,7r,8s,9s,16s,z)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-((e)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)oxacyclohexadec-13-ene-2,6-dione
AC-22616
AKOS025401598
EX-A495
(4s,7r,8s,9s,13z,16s)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-(1e)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl-oxacyclohexadec-13-ene-2,6-dione
mfcd27976357
(4s,7r,8s,9s,13z,16s)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(e)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)ethenyl]oxacyclohexadec-13-ene-2,6-dione
DTXSID70880053
epothilone-d
desoxyepothilone b; (3s,7s,14s,15s,16r)-3,15-dihydroxy-2,2,10,14,16-pentamethyl-7-[1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-6-oxacyclohexadec-9-ene-1,5-dione
A880448

Roles (1)

RoleDescription
microtubule-stabilising agentAny substance that interacts with tubulin to promote polymerisation of microtubules.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
epothiloneAny member of the class of 16-membered macrolide natural products, or their analogues, normally containing a double bond or its epoxide at positions 12-13 and bearing hydroxy groups at positions 4 and 8, methyl groups at positions 5, 5, 7, and 9, an oxo group at position 6, and a 1-(2-substituted-1,3-thiazol-4-yl)prop-1-en-2-yl substituent at position 15.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency0.01310.00529.466132.9993AID1347411
Interferon betaHomo sapiens (human)Potency0.01310.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (30)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347414qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID772394Stabilization of microtubule in HEK293 cells assessed as increase in acetylated alpha-tubulin at 100 nM after 4 hrs by ELISA2013ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9
MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications.
AID361147Cytotoxicity against camptothecin-resistant human CCRF-CEM cells after 3 days by SRB assay2002Journal of natural products, Jul, Volume: 65, Issue:7
A new cytotoxic epothilone from modified polyketide synthases heterologously expressed in Myxococcus xanthus.
AID356491Cytotoxicity against human NCI/ADR cells after 3 days by SRB assay2003Journal of natural products, Oct, Volume: 66, Issue:10
Isolation and characterization of new epothilone analogues from recombinant Myxococcus xanthus fermentations.
AID771385Cytotoxicity against human MCF7 cells after 72 hrs2013European journal of medicinal chemistry, Oct, Volume: 68Epothilone D and its 9-Methyl analogues: combinatorial syntheses, conformation, and biological activities.
AID361142Cytotoxicity against human SF268 cells after 3 days by SRB assay2002Journal of natural products, Jul, Volume: 65, Issue:7
A new cytotoxic epothilone from modified polyketide synthases heterologously expressed in Myxococcus xanthus.
AID361144Cytotoxicity against human HL60 cells after 3 days by SRB assay2002Journal of natural products, Jul, Volume: 65, Issue:7
A new cytotoxic epothilone from modified polyketide synthases heterologously expressed in Myxococcus xanthus.
AID159565Induction of polymerization of porcine brain-derived microtubule protein by 2 uM epothilone B2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and biological evaluation of highly potent analogues of epothilones B and D.
AID94006Concentration required to inhibit the growth of paclitaxel-sensitive human epidermoid carcinoma cells KB-31 by 50 percent (72 hr exposure)2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and biological evaluation of highly potent analogues of epothilones B and D.
AID361145Cytotoxicity against mitoxantrone-resistant human HL60 cells after 3 days by SRB assay2002Journal of natural products, Jul, Volume: 65, Issue:7
A new cytotoxic epothilone from modified polyketide synthases heterologously expressed in Myxococcus xanthus.
AID771383Inhibition of tubulin polymerization (unknown origin) at 5 uM2013European journal of medicinal chemistry, Oct, Volume: 68Epothilone D and its 9-Methyl analogues: combinatorial syntheses, conformation, and biological activities.
AID772388Plasma concentration in CD1 mouse at 5 mg/kg, ip administered as single dose at 16 hrs2013ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9
MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications.
AID356493Cytotoxicity against human NCI-H460 cells after 3 days by SRB assay2003Journal of natural products, Oct, Volume: 66, Issue:10
Isolation and characterization of new epothilone analogues from recombinant Myxococcus xanthus fermentations.
AID1182022Inhibition of human P-glycoprotein expressed in NCI/ADR-RES cells assessed as reduction of calcein-AM transport after 20 mins by fluorescence assay2014Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14
Brain-penetrant, orally bioavailable microtubule-stabilizing small molecules are potential candidate therapeutics for Alzheimer's disease and related tauopathies.
AID361141Cytotoxicity against human NCI/ADR-RES cells after 3 days by SRB assay2002Journal of natural products, Jul, Volume: 65, Issue:7
A new cytotoxic epothilone from modified polyketide synthases heterologously expressed in Myxococcus xanthus.
AID361140Cytotoxicity against human MCF7 cells after 3 days by SRB assay2002Journal of natural products, Jul, Volume: 65, Issue:7
A new cytotoxic epothilone from modified polyketide synthases heterologously expressed in Myxococcus xanthus.
AID159417Concentrations required to induce 50 percent polymerization of porcine brain-derived micro-tubule protein2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and biological evaluation of highly potent analogues of epothilones B and D.
AID361143Cytotoxicity against human NCI-H460 cells after 3 days by SRB assay2002Journal of natural products, Jul, Volume: 65, Issue:7
A new cytotoxic epothilone from modified polyketide synthases heterologously expressed in Myxococcus xanthus.
AID361146Cytotoxicity against human CCRF-CEM cells after 3 days by SRB assay2002Journal of natural products, Jul, Volume: 65, Issue:7
A new cytotoxic epothilone from modified polyketide synthases heterologously expressed in Myxococcus xanthus.
AID1182021Induction of microtubule stabilization in human QBI293 cells assessed as increase in acetylated alpha-tubulin at 100 nM after 4 hrs by immunofluorescence assay relative to control2014Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14
Brain-penetrant, orally bioavailable microtubule-stabilizing small molecules are potential candidate therapeutics for Alzheimer's disease and related tauopathies.
AID356712Cytotoxicity against mouse L929 cells2001Journal of natural products, Jul, Volume: 64, Issue:7
New natural epothilones from Sorangium cellulosum, strains So ce90/B2 and So ce90/D13: isolation, structure elucidation, and SAR studies.
AID772387Drug uptake in CD1 mouse brain at 5 mg/kg, ip administered as single dose at 16 hrs2013ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9
MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications.
AID356490Cytotoxicity against human MCF7 cells after 3 days by SRB assay2003Journal of natural products, Oct, Volume: 66, Issue:10
Isolation and characterization of new epothilone analogues from recombinant Myxococcus xanthus fermentations.
AID772391Plasma concentration in CD1 mouse at 5 mg/kg, ip administered as single dose at 4 hrs2013ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9
MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications.
AID356492Cytotoxicity against human SF268 cells after 3 days by SRB assay2003Journal of natural products, Oct, Volume: 66, Issue:10
Isolation and characterization of new epothilone analogues from recombinant Myxococcus xanthus fermentations.
AID772395Stabilization of microtubule in HEK293 cells assessed as increase in acetylated alpha-tubulin after 4 hrs by ELISA2013ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9
MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications.
AID772386Drug uptake in CD1 mouse brain at 5 mg/kg, ip administered as single dose at 4 hrs2013ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9
MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications.
AID94043Concentration required to inhibit the growth of paclitaxel-resistant human epidermoid carcinoma cells KB-8511 by 50 percent (72 hr exposure)2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and biological evaluation of highly potent analogues of epothilones B and D.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (98)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (2.04)18.2507
2000's52 (53.06)29.6817
2010's35 (35.71)24.3611
2020's9 (9.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (3.03%)5.53%
Reviews15 (15.15%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other81 (81.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open-label Study to Evaluate the Effect of Combination Therapy With Epothilone D and Herceptin on Tumor Response in Patients With HER-2 Overexpressing Locally Advanced or Metastatic Breast Cancer[NCT00337649]Phase 1/Phase 227 participants (Actual)Interventional2004-05-31Completed
A Phase II Study Of KOS-862 (Epothilone D), Administered Intravenously Weekly For 3 Weeks Every 4 Weeks, In The Second-Line Treatment Of Patients With Advanced Or Metastatic Colorectal Carcinoma (CRC)[NCT00077259]Phase 20 participants Interventional2003-10-31Completed
A Phase 2 Study of KOS-862 Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, in Patients With Hormone Resistant Prostate Cancer Who Have Progressed Following Initial Therapy for Metastatic Disease[NCT00104130]Phase 253 participants Interventional2004-12-31Terminated
A Phase II Study of KOS-862, Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, in Patients With Non-Small Cell Lung Cancer Who Have Progressed Following Initial Therapy for Advanced or Metastatic Disease[NCT00081107]Phase 20 participants Interventional2003-12-31Completed
A Phase 2 Study of KOS-862, Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, in Patients With Non-Small Cell Lung Cancer Who Have Progressed Following Initial Therapy for Advanced or Metastatic Disease[NCT00080509]Phase 285 participants Interventional2003-12-31Terminated
A Phase 1, Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Epothilone D in Patients With Advanced Solid Tumors[NCT00030173]Phase 145 participants Interventional2001-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
paclitaxel[no description available]medium100taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
epothilone b[no description available]high260epothilone;
epoxide		antineoplastic agent;
apoptosis inducer;
microtubule-stabilising agent
epothilone a[no description available]high940epothilone;
epoxide		antineoplastic agent;
metabolite;
microtubule-stabilising agent;
tubulin modulator
epothilone a[no description available]high943epothilone;
epoxide		antineoplastic agent;
metabolite;
microtubule-stabilising agent;
tubulin modulator
epothilone e[no description available]medium40
desoxyepothilone a[no description available]medium80epothilone
epothilone f[no description available]medium30
discodermolide[no description available]medium10diterpenoid
dictyostatin[no description available]medium10
verapamil[no description available]medium20aromatic ether;
nitrile;
polyether;
tertiary amino compound
cyclosporine[no description available]medium10homodetic cyclic peptideanti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite
cevipabulin[no description available]medium10
2-(2,6-diisopropylphenyl)-5-hydroxy-1h-isoindole-1,3-dione[no description available]medium10
dimethyl sulfoxide[no description available]medium10sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger
ixabepilone[no description available]medium601,3-thiazoles;
beta-hydroxy ketone;
epoxide;
lactam;
macrocycle		antineoplastic agent;
microtubule-destabilising agent
alpha-synuclein[no description available]medium10
nocodazole[no description available]medium20aromatic ketone;
benzimidazoles;
carbamate ester;
thiophenes		antimitotic;
antineoplastic agent;
microtubule-destabilising agent;
tubulin modulator
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine[no description available]medium10methylpyridines;
phenylpyridine;
tetrahydropyridine		neurotoxin
chromium[no description available]medium10chromium group element atom;
metal allergen		micronutrient
phenylmethylsulfonyl fluoride[no description available]medium10acyl fluorideserine proteinase inhibitor
methamphetamine[no description available]medium10amphetamines;
secondary amine		central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic
3,4-dihydroxyphenylacetic acid[no description available]medium10catechols;
dihydroxyphenylacetic acid		human metabolite
homovanillic acid[no description available]medium10guaiacols;
monocarboxylic acid		human metabolite;
mouse metabolite
davunetide[no description available]medium10oligopeptide
methylene blue[no description available]medium10organic chloride saltacid-base indicator;
antidepressant;
antimalarial;
antimicrobial agent;
antioxidant;
cardioprotective agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 4.6.1.2 (guanylate cyclase) inhibitor;
fluorochrome;
histological dye;
neuroprotective agent;
physical tracer
thiazoles[no description available]medium2001,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
boron[no description available]medium10boron group element atom;
metalloid atom;
nonmetal atom		micronutrient
bms 310705[no description available]medium40
hydroxyl radical[no description available]medium10oxygen hydride;
oxygen radical;
reactive oxygen species
discodermolide[no description available]medium20
peloruside a[no description available]medium20
carbamates[no description available]medium20amino-acid anion
alkenes[no description available]medium50
carboplatin[no description available]medium11
mannose[no description available]medium10D-aldohexose;
D-mannose;
mannopyranose		metabolite
fluoxetine[no description available]medium10(trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound
molybdenum[no description available]medium10chromium group element atommicronutrient
erythromycin[no description available]medium10cyclic ketone;
erythromycin
sirolimus[no description available]medium10antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
heme[no description available]medium10
silicon[no description available]medium10carbon group element atom;
metalloid atom;
nonmetal atom
palladium[no description available]medium10metal allergen;
nickel group element atom;
platinum group metal atom
iodine[no description available]medium10halide anion;
monoatomic iodine		human metabolite
cysteamine[no description available]medium10amine;
thiol		geroprotector;
human metabolite;
mouse metabolite;
radiation protective agent
proline[no description available]medium10amino acid zwitterion;
glutamine family amino acid;
L-alpha-amino acid;
proline;
proteinogenic amino acid		algal metabolite;
compatible osmolytes;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
leucine[no description available]medium10amino acid zwitterion;
L-alpha-amino acid;
leucine;
proteinogenic amino acid;
pyruvate family amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
valine[no description available]medium10L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
docetaxel anhydrous[no description available]medium11secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
thymidine[no description available]medium10pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
salicylic acid[no description available]medium10monohydroxybenzoic acidalgal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite
capecitabine[no description available]medium20carbamate ester;
cytidines;
organofluorine compound		antimetabolite;
antineoplastic agent;
prodrug
fluorouracil[no description available]medium20nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
deoxycytidine[no description available]medium20pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
methylmalonyl-coenzyme a[no description available]medium10
methyl oleate[no description available]medium10fatty acid methyl ester
tilivalline[no description available]low00indole alkaloid;
indoles;
phenols;
pyrrolobenzodiazepine		bacterial metabolite;
microtubule-stabilising agent;
toxin
laulimalide[no description available]low00carboxylic ester;
epoxide;
macrolide;
secondary alcohol;
secondary allylic alcohol		animal metabolite;
antimitotic;
antineoplastic agent;
marine metabolite;
microtubule-stabilising agent
cabazitaxel[no description available]low00tetracyclic diterpenoidantineoplastic agent;
microtubule-stabilising agent
ConditionIndicatedRelationship StrengthStudiesTrials
Acute Brain Injuries0low10
Acute Confusional Senile Dementia0low100
Acute Lymphoid Leukemia0low10
Acute Promyelocytic Leukemia0low10
Adenocarcinoma0low10
Adenocarcinoma, Basal Cell0low10
Adenocarcinoma, Granular Cell0low10
Adenocarcinoma, Oxyphilic0low10
Adenocarcinoma, Tubular0low10
Adenoma, Malignant0low10
Aging0low10
ALL, Childhood0low10
ALS - Amyotrophic Lateral Sclerosis0low20
Alzheimer Dementia0low100
Alzheimer Disease0low100
Alzheimer Disease, Early Onset0low100
Alzheimer Disease, Late Onset0low100
Alzheimer Sclerosis0low100
Alzheimer Syndrome0low100
Alzheimer Type Senile Dementia0low100
Alzheimer-Type Dementia (ATD)0low100
Alzheimer's Disease0low100
Alzheimer's Disease, Focal Onset0low100
Alzheimer's Diseases0low100
AML M30low10
Amyotrophic Lateral Sclerosis0low20
Amyotrophic Lateral Sclerosis With Dementia0low20
Amyotrophic Lateral Sclerosis-Parkinsonism-Dementia Complex 10low20
Amyotrophic Lateral Sclerosis, Guam Form0low20
Amyotrophic Lateral Sclerosis, Parkinsonism-Dementia Complex of Guam0low20
Anterior Circulation Transient Ischemic Attack0low10
ATLL0low20
Autism0low10
Autism Spectrum Disorder0low10
Autism Spectrum Disorders0low10
Autism, Early Infantile0low10
Autism, Infantile0low10
Autistic Disorder0low10
Autistic Spectrum Disorder0low10
Autosomal Dominant Juvenile Parkinson Disease0low10
Autosomal Dominant Juvenile Parkinsonism0low10
Autosomal Dominant Parkinsonism0low10
Autosomal Recessive Juvenile Parkinson Disease0low10
Autosomal Recessive Juvenile Parkinsonism0low10
Autosomal Recessive Parkinsonism0low10
Benign Neoplasms0medium92
Benign Neoplasms, Brain0low10
Bone Cancer0low10
Bone Neoplasms0low10
Brain Cancer0low10
Brain Injuries0low10
Brain Injuries, Acute0low10
Brain Injuries, Focal0low10
Brain Lacerations0low10
Brain Metastases0low10
Brain Neoplasm, Primary0low10
Brain Neoplasms0low10
Brain Neoplasms, Benign0low10
Brain Neoplasms, Malignant0low10
Brain Neoplasms, Malignant, Primary0low10
Brain Neoplasms, Primary Malignant0low10
Brain Stem Ischemia, Transient0low10
Brain Stem Transient Ischemic Attack0low10
Brain TIA0low10
Brain Tumor, Primary0low10
Brain Tumor, Recurrent0low10
Brain Tumors0low10
Brainstem Ischemia, Transient0low10
Brainstem Transient Ischemic Attack0low10
Breast Cancer0low60
Breast Carcinoma0low60
Breast Tumors0low60
Cancer0medium92
Cancer of Bone0low10
Cancer of Brain0low10
Cancer of Breast0low60
Cancer of Colon0low10
Cancer of Lung0low20
Cancer of Ovary0low10
Cancer of Prostate0medium11
Cancer of the Bone0low10
Cancer of the Brain0low10
Cancer of the Breast0low60
Cancer of the Colon0low10
Cancer of the Lung0low20
Cancer of the Ovary0low10
Cancer of the Prostate0medium11
Carcinoma, Cribriform0low10
Carcinoma, Granular Cell0low10
Carcinoma, Tubular0low10
Carotid Arteriopathies, Traumatic0low10
Carotid Artery Injuries0low10
Carotid Circulation Transient Ischemic Attack0low10
Carotid False Aneurysm0low10
Carotid Pseudoaneurysm0low10
Cell Transformation, Neoplastic0low10
Cerebral Ischemia, Transient0low10
Charcot Disease0low20
Chromosomal Instability0low10
Chromosomal Stability0low10
Chromosome 6-Linked Autosomal Recessive Parkinsonism0low10
Chromosome Instability0low10
Chromosome Stability0low10
Cognition Disorders0low30
Colon Cancer0low10
Colon Neoplasms0low10
Colonic Cancer0low10
Colonic Neoplasms0low10
Crescendo Transient Ischemic Attacks0low10
Degenerative Diseases, Central Nervous System0low10
Degenerative Diseases, Nervous System0low10
Degenerative Diseases, Neurologic0low10
Degenerative Diseases, Spinal Cord0low10
Degenerative Neurologic Diseases0low10
Degenerative Neurologic Disorders0low10
Dementia With Amyotrophic Lateral Sclerosis0low20
Dementia, Alzheimer Type0low100
Dementia, Presenile0low100
Dementia, Primary Senile Degenerative0low100
Dementia, Senile0low100
Depression0low10
Disease Exacerbation0medium51
Disease Models, Animal0low90
Disease Progression0medium51
Early Onset Alzheimer Disease0low100
Encephalopathy, Toxic0low10
Experimental Neoplasms0low10
Experimental Parkinson Disease0low10
Experimental Parkinsonism0low10
Experimental Parkinsonism, MPTP-Induced0low10
False Aneurysm, Carotid0low10
Familial Alzheimer Disease (FAD)0low100
Familial Juvenile Parkinsonism0low10
Familial Parkinson Disease, Autosomal Recessive0low10
Focal Brain Injuries0low10
Focal Onset Alzheimer's Disease0low100
Gehrig's Disease0low20
Germinoblastoma0medium11
Glial Cell Tumors0low20
Glioma0low20
Guam Disease0low20
Guam Form of Amyotrophic Lateral Sclerosis0low20
HTLV I Associated T Cell Leukemia Lymphoma0low20
HTLV-Associated Leukemia-Lymphoma0low20
HTLV-I-Associated T-Cell Leukemia-Lymphoma0low20
Human Mammary Carcinoma0low60
Human T Lymphotropic Virus Associated Leukemia Lymphoma0low20
Human T Lymphotropic Virus-Associated Leukemia-Lymphoma0low20
Human T-Cell Leukemia-Lymphoma0low20
Hyperplasia0low10
Injuries, Acute Brain0low10
Injuries, Brain0low10
Injuries, Carotid Artery0low10
Injuries, Spinal Cord0low20
Intracranial Neoplasms0low10
Ischemic Attack, Transient0low10
Juvenile Parkinson Disease0low10
Juvenile Parkinson Disease, Autosomal Dominant0low10
Juvenile Parkinson Disease, Autosomal Recessive0low10
Juvenile Parkinsonism, Autosomal Dominant0low10
Juvenile Parkinsonism, Autosomal Recessive0low10
Kanner's Syndrome0low10
Late Onset Alzheimer Disease0low100
Leukemia Lymphoma, Adult T Cell0low20
Leukemia Lymphoma, T Cell, Acute, HTLV I Associated0low20
Leukemia P3880low10
Leukemia-Lymphoma, Adult T-Cell0low20
Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated0low20
Leukemia, Acute Lymphoblastic0low10
Leukemia, Acute Promyelocytic0low10
Leukemia, Adult T-Cell0low20
Leukemia, Lymphoblastic0low10
Leukemia, Lymphoblastic, Acute0low10
Leukemia, Lymphoblastic, Acute, L10low10
Leukemia, Lymphoblastic, Acute, L20low10
Leukemia, Lymphoblastic, Acute, Philadelphia-Positive0low10
Leukemia, Lymphoblastic, Acute, T Cell0low10
Leukemia, Lymphoblastic, Acute, T-Cell0low10
Leukemia, Lymphocytic, Acute0low10
Leukemia, Lymphocytic, Acute T Cell0low10
Leukemia, Lymphocytic, Acute, L10low10
Leukemia, Lymphocytic, Acute, L20low10
Leukemia, Lymphocytic, Acute, T-Cell0low10
Leukemia, Lymphocytic, T Cell0low10
Leukemia, Lymphocytic, T-Cell0low10
Leukemia, Lymphoid, Acute0low10
Leukemia, Myeloid, Acute, M30low10
Leukemia, Progranulocytic0low10
Leukemia, Promyelocytic, Acute0low10
Leukemia, T-Cell0low10
Leukemia, T-Cell, Acute0low10
Lou Gehrig Disease0low20
Lou Gehrig's Disease0low20
Lou-Gehrigs Disease0low20
Lung Cancer0low20
Lymphoblastic Leukemia0low10
Lymphoblastic Leukemia, Acute0low10
Lymphoblastic Leukemia, Acute, Adult0low10
Lymphoblastic Leukemia, Acute, Childhood0low10
Lymphoblastic Leukemia, Acute, L10low10
Lymphoblastic Leukemia, Acute, L20low10
Lymphoblastic Leukemia, Acute, T Cell0low10
Lymphoblastic Leukemia, Acute, T-Cell0low10
Lymphoblastic Lymphoma0low10
Lymphocytic Leukemia, Acute0low10
Lymphocytic Leukemia, L10low10
Lymphocytic Leukemia, L20low10
Lymphocytic Leukemia, T Cell, Acute0low10
Lymphocytic Leukemia, T-Cell0low10
Lymphocytic Leukemia, T-Cell, Acute0low10
Lymphoma0medium11
Lymphoma, Lymphoblastic0low10
Lymphoma, Malignant0medium11
M3 ANLL0low10
Malignancy0medium92
Malignant Glioma0low20
Malignant Neoplasm of Breast0low60
Malignant Neoplasms0medium92
Malignant Neoplasms, Brain0low10
Malignant Primary Brain Neoplasms0low10
Malignant Primary Brain Tumors0low10
Malignant Tumor of Breast0low60
Mammary Cancer0low60
Mammary Carcinoma, Human0low60
Mammary Neoplasm, Human0low60
Mammary Neoplasms, Human0low60
Metastase0medium31
Metastases, Neoplasm0medium31
Metastasis0medium31
Metastasis, Neoplasm0medium31
Mixed Glioma0low20
Motor Neuron Disease, Amyotrophic Lateral Sclerosis0low20
MPTP Neurotoxicity Syndrome0low10
MPTP Poisoning0low10
MPTP-Induced Degeneration of the Striatum0low10
MPTP-Induced Experimental Parkinsonism0low10
MPTP-Induced Parkinsonism0low10
Multiple System Atrophy0low10
Multiple System Atrophy Syndrome0low10
Multisystem Atrophy0low10
Multisystemic Atrophy0low10
Myeloid Leukemia, Acute, M30low10
Myelopathy, Traumatic0low20
Neoplasia0medium92
Neoplasm0medium92
Neoplasm Metastases0medium31
Neoplasm Metastasis0medium31
Neoplasms, Benign0medium92
Neoplasms, Bone0low10
Neoplasms, Brain0low10
Neoplasms, Brain, Benign0low10
Neoplasms, Brain, Malignant0low10
Neoplasms, Brain, Primary0low10
Neoplasms, Breast0low60
Neoplasms, Colonic0low10
Neoplasms, Experimental0low10
Neoplasms, Intracranial0low10
Neoplasms, Lung0low20
Neoplasms, Ovarian0low10
Neoplasms, Prostate0medium11
Neoplasms, Prostatic0medium11
Neoplasms, Pulmonary0low20
Neoplastic Cell Transformation0low10
Neoplastic Transformation, Cell0low10
Nerve Degeneration0low30
Nervous System Degenerative Diseases0low10
Nervous System Poisoning0low10
Neuroblastoma0low10
Neurodegenerative Diseases0low10
Neurodegenerative Disorders0low10
Neurologic Degenerative Conditions0low10
Neurologic Degenerative Diseases0low10
Neurologic Diseases, Degenerative0low10
Neuron Degeneration0low30
Neurotoxic Disorders0low10
Neurotoxicity Syndrome, MPTP0low10
Neurotoxicity Syndromes0low10
Neurotoxin Diseases0low10
Neurotoxin Disorders0low10
Ovarian Cancer0low10
Ovarian Neoplasms0low10
Ovary Cancer0low10
Ovary Neoplasms0low10
Overinclusion0low30
P388D(1) Leukemia0low10
Parkinson Disease 20low10
Parkinson Disease 2, Autosomal Recessive Juvenile0low10
Parkinson Disease Autosomal Recessive, Early Onset0low10
Parkinson Disease, Autosomal Dominant. Juvenile0low10
Parkinson Disease, Experimental0low10
Parkinson Disease, Familial, Autosomal Recessive0low10
Parkinson Disease, Juvenile0low10
Parkinson Disease, Juvenile, Autosomal Dominant0low10
Parkinson Disease, Juvenile, Autosomal Recessive0low10
Parkinsonian Diseases0low10
Parkinsonian Disorders0low10
Parkinsonian Syndrome0low10
Parkinsonian Syndromes0low10
Parkinsonism0low10
Parkinsonism, Early Onset, with Diurnal Fluctuation0low10
Parkinsonism, Early-Onset, With Diurnal Fluctuation0low10
Parkinsonism, Experimental0low10
Parkinsonism, Juvenile0low10
Parkinsonism, Juvenile, Autosomal Dominant0low10
Parkinsonism, Juvenile, Autosomal Recessive0low10
Poisoning, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine0low10
Poisoning, Nervous System0low10
Post-Traumatic Myelopathy0low20
Posterior Circulation Transient Ischemic Attack0low10
Precursor Cell Lymphoblastic Leukemia-Lymphoma0low10
Precursor T-Cell Lymphoblastic Leukemia0low10
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma0low10
Precursor T-Cell Lymphoblastic Lymphoma0low10
Presenile Alzheimer Dementia0low100
Primary Brain Neoplasms0low10
Primary Malignant Brain Neoplasms0low10
Primary Malignant Brain Tumors0low10
Primary Senile Degenerative Dementia0low100
Progranulocytic Leukemia0low10
Promyelocytic Leukemia, Acute0low10
Prostate Cancer0medium11
Prostate Neoplasms0medium11
Prostatic Cancer0medium11
Prostatic Neoplasms0medium11
Protein Aggregation, Pathological0low10
Pulmonary Cancer0low20
Pulmonary Neoplasms0low20
Ramsay Hunt Paralysis Syndrome0low10
Reticulolymphosarcoma0medium11
Sarcoma, Germinoblastic0medium11
Senile Dementia, Acute Confusional0low100
Senile Dementia, Alzheimer Type0low100
Sensitivity and Specificity0low30
Spinal Cord Contusion0low20
Spinal Cord Injuries0low20
Spinal Cord Laceration0low20
Spinal Cord Transection0low20
Spinal Cord Trauma0low20
T Cell Leukemia Lymphoma, HTLV I Associated0low20
T Cell Leukemia, Adult0low20
T Lymphocytic Leukemia0low10
T-ALL0low10
T-Cell Acute Lymphocytic Leukemia0low10
T-Cell Leukemia0low10
T-Cell Leukemia-Lymphoma, Adult0low20
T-Cell Leukemia-Lymphoma, HTLV-I-Associated0low20
T-Cell Leukemia, Acute0low10
T-Cell Leukemia, Adult0low20
T-Lymphocytic Leukemia0low10
T-Lymphocytic Leukemia, Acute0low10
Tauopathies0low80
Tauopathy0low80
TIA (Transient Ischemic Attack)0low10
Toxic Encephalitis0low10
Transformation, Neoplastic Cell0low10
Transient Ischemic Attack0low10
Transient Ischemic Attack, Anterior Circulation0low10
Transient Ischemic Attack, Brain Stem0low10
Transient Ischemic Attack, Brainstem0low10
Transient Ischemic Attack, Carotid Circulation0low10
Transient Ischemic Attack, Posterior Circulation0low10
Transient Ischemic Attack, Vertebrobasilar Circulation0low10
Transient Ischemic Attacks, Crescendo0low10
Trauma, Carotid Artery0low10
Tumorigenic Transformation0low10
Tumors0medium92
Tumors, Breast0low60
Vertebrobasilar Circulation Transient Ischemic Attack0low10

Research Highlights

Safety/Toxicity (1)

ArticleYear
The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice.
The Journal of neuroscience : the official journal of the Society for Neuroscience, Mar-14, Volume: 32, Issue: 11		2012
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (2)

ArticleYear
Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma.
Investigational new drugs, Volume: 30, Issue: 6		2012
Simultaneous determination of epothilone D and its hydrolytic metabolite in human plasma by high performance liquid chromatography-tandem mass spectrometry for pharmacokinetic studies.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, Nov-01, Volume: 877, Issue: 29		2009
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (1)

ArticleYear
Brain-penetrant, orally bioavailable microtubule-stabilizing small molecules are potential candidate therapeutics for Alzheimer's disease and related tauopathies.
Journal of medicinal chemistry, Jul-24, Volume: 57, Issue: 14		2014
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (3)

ArticleYear
Epothilone D alters normal growth, viability and microtubule dependent intracellular functions of cortical neurons in vitro.
Scientific reports, 01-22, Volume: 10, Issue: 1		2020
Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies.
Biochemical Society transactions, Volume: 40, Issue: 4		2012
Epothilone D affects cell cycle and microtubular pattern in plant cells.
Journal of experimental botany, Volume: 56, Issue: 418		2005
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]